Oh really? Is that the only possible explanation: that MSB have drained shareholders and are moving on ...like a bunch of traders?
Seriously?
- Australia is an immature nation for biotechs. It also has very conservative fund managers who don't index-hug the top 200 on the ASX and don't really understand the sector.
- Currently there is a mania for yield which is squeezing very highly promising companies.
- Australia is also a very small market by global standards.
As has been repeatedly stated in these threads by myself and some others.
We should all understand this IMO, but it seems some will not take it into account.
BTW now I recall that the CEO said something cryptic about international markets at the AGM.
Even worse, page-2
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.05 | $5.002M | 4.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5697 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
-0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.11 | $1.06 | 1181223 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MSB (ASX) Chart |